Author

Alberto Fernández‐Medarde

Consejo Superior de Investigaciones CientíficasORCID 0000-0002-1230-5501Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Alba Díaz-Aguilera· 2 shared Andrea Olarte-San JuaniD· 2 shared Carmela GómeziD· 2 shared Eugenio SantosiD· 2 shared Nuria CalzadaiD· 2 shared Rósula García‐NavasiD· 2 shared Anabel Clemente-Serrano· 1 shared Belen Zamora-ValdiviesoiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

Alba Díaz-Aguilera

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologyCell Death and DiseasePeer-reviewedAug 12, 2026

Concomitant ablation of SOS1 and SOS2 triggers a lethal phenotype involving compromised intestinal integrity and widespread septicemia

Andrea Olarte-San Juan, Pablo Rodríguez-Ramos, Alba Díaz-Aguilera…·Rósula García‐Navas

This study shows that deleting both SOS1 and SOS2 in mice causes intestinal damage, bacterial leakage, and septicemia, but stemness-enhancing therapies improve survival.

DOI 10.1038/s41419-026-09185-z

mouseexperimental assay

Cancer BiologyCell Death and DiseasePeer-reviewedAug 12, 2026

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia

Rósula García‐Navas, Carmela Gómez, Anabel Clemente-Serrano…·Eugenio Santos

This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.

DOI 10.1038/s41419-026-09170-6

mousehuman